Registration
Advertiser Disclosure

Alnylam Pharmaceuticals (ALNY) News Today: Latest Market and Industry Updates

224.03
2.9200
1.29 %
At close 10/23
USD
USD
NASDAQ
Daily range
222.00 Arrow from to Icon 229.39
Weekly range
222.00 Arrow from to Icon 238.95
Live Price Short-Term Long-Term Signals Earnings Price History News
What's behind Alnylam Pharmaceuticals's latest 3.5% stock pullback?
  • Anton Kharitonov
  • 02.10.2026
What's behind Alnylam Pharmaceuticals's latest 3.5% stock pullback?
Alnylam Pharmaceuticals, Inc. (ALNY) declined 3.55% as concerns about its elevated valuation continued to weigh on sentiment. The downtrend is supported by the stock's position below all major ...
#Forecast
U.S. job market slowdown prompts defensive income strategy
  • Oksana Koneva
  • 30.09.2026
U.S. job market slowdown prompts defensive income strategy
Fresh labor and consumer sentiment data point to a quieter U.S. economy ahead of Friday's jobs report, with job openings falling and households turning more cautious. The combination signals ...
#Labor Market #USA #Coca‑Cola
What's behind Alnylam Pharmaceuticals' latest 3.0% stock pullback?
  • Viktoras Karapetjanc
  • 15.09.2026
What's behind Alnylam Pharmaceuticals' latest 3.0% stock pullback?
Alnylam Pharmaceuticals, Inc. (ALNY) dropped 2.95% as sellers maintained pressure, even as recent news centered on comparisons of its marketed products and development pipeline without new product ...
#Forecast
What's behind Alnylam Pharmaceuticals' latest 3.1% stock surge?
  • Ciaran Ryan
  • 21.08.2026
What's behind Alnylam Pharmaceuticals' latest 3.1% stock surge?
Alnylam Pharmaceuticals, Inc. (ALNY) jumped 3.07% after securing FDA approval for its vutrisiran therapy for cardiomyopathy linked to amyloidosis, driving renewed buying interest. The rebound ...
#Forecast
What's behind Alnylam Pharmaceuticals' latest 3.4% stock surge?
  • Parshwa Turakhiya
  • 05.08.2026
What's behind Alnylam Pharmaceuticals' latest 3.4% stock surge?
Alnylam Pharmaceuticals, Inc. (ALNY) advanced 3.4% after reporting second-quarter TTR amyloidosis franchise revenues above $1 billion, driven by AMVUTTRA uptake. The rebound looks limited, as the ...
#Forecast
Alnylam Pharmaceuticals shares gain more than 6% after energetic rebound from deeply oversold levels
  • Andreas Kristo
  • 03.08.2026
Alnylam Pharmaceuticals shares gain more than 6% after energetic rebound from deeply oversold levels
Alnylam Pharmaceuticals (ALNY) surged 6.33% as buyers responded to an oversold technical setup, driving an energetic session high. The rebound looks limited, with the stock still trading well ...
#Forecast
Why is Alnylam Pharmaceuticals stock down 3.8% today?
  • Ezequiel Gomes
  • 17.07.2026
Why is Alnylam Pharmaceuticals stock down 3.8% today?
Alnylam Pharmaceuticals, Inc. (ALNY) fell 3.81% as bearish technical momentum built, even as recent company results showed financial and operational strength. The negative pressure is supported by ...
#Forecast
Alnylam Pharmaceuticals stock falls nearly 4% as selling pressure intensifies despite mixed technical signals
  • Emilio Ghigini
  • 10.07.2026
Alnylam Pharmaceuticals stock falls nearly 4% as selling pressure intensifies despite mixed technical signals
Alnylam Pharmaceuticals, Inc. (ALNY) dropped 3.88% as selling pressure intensified against a mixed technical backdrop. The decline is contradicted by short-term bullish momentum signals, with ...
#Forecast
ALNY climbs almost 11% after rally above key moving averages boosts buying interest
  • Ashutosh Sureka
  • 09.07.2026
ALNY climbs almost 11% after rally above key moving averages boosts buying interest
Alnylam Pharmaceuticals, Inc. (ALNY) surged 10.83% today as technical buying and strong upside momentum drove renewed demand. The rally is supported in the short and medium term by the stock ...
#Forecast
Alnylam Pharmaceuticals stock price forecast: $296.76 resistance as ALNY stays flat
  • Oleg Tkachenko
  • 01.07.2026
Alnylam Pharmaceuticals stock price forecast: $296.76 resistance as ALNY stays flat
Alnylam Pharmaceuticals (ALNY) stock is trading at $296.44, posting a daily increase of 0.99%. The price remains above key short- and medium-term moving averages, ...
#Forecast
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers